There are 2137 resources available
1345P - Preliminary safety and activity of CLN-081 in NSCLC with EGFR exon 20 insertion mutations (Ins20)
Presenter: Zofia Piotrowska
Session: E-Poster Display
Resources:
Abstract
1346P - Comparison of clinical outcomes of patients with METΔex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients
Presenter: Juergen Wolf
Session: E-Poster Display
Resources:
Abstract
1347P - Health-related quality of life (HRQoL) in patients (pts) with NSCLC harboring MET exon 14 skipping (METex14) treated with tepotinib
Presenter: Marina Garassino
Session: E-Poster Display
Resources:
Abstract
1348P - Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK+ non-small cell lung cancer (NSCLC) in the ASCEND-8 trial
Presenter: Byong Chul Cho
Session: E-Poster Display
Resources:
Abstract
1349P - Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort
Presenter: Nicolas Girard
Session: E-Poster Display
Resources:
Abstract
1350P - Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC)
Presenter: Sanjay Popat
Session: E-Poster Display
Resources:
Abstract
1351P - The impact of BRCA mutation status on NSCLC disease course and response to therapy
Presenter: Roi Tschernichovsky
Session: E-Poster Display
Resources:
Abstract
1352P - Circulating tumour (ct) DNA next generation sequencing (NGS) in advanced non-small cell lung cancer (mNSCLC): A UK single institution experience
Presenter: Wanyuan Cui
Session: E-Poster Display
Resources:
Abstract
1353P - Clinical utility of circulating tumour (ct) DNA next generation sequencing (NGS) for target identification in diagnostic and acquired resistance settings in metastatic NSCLC (mNSCLC): Single centre experience
Presenter: Nadza Tokaca
Session: E-Poster Display
Resources:
Abstract
1354P - Detection of EGFR T790M in EGFR activating mutation-positive advanced non-small cell lung cancer (NSCLC): Comparison between two assays on circulating tumour (ct)DNA
Presenter: Sandrine Charpentier
Session: E-Poster Display
Resources:
Abstract